Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 136252, 4 pages
http://dx.doi.org/10.1155/2010/136252
Case Report

Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy

1Department of Hematology, Faculty of Medicine, University of São Paulo, SP 05403-000, Brazil
2Fundação Pro-Sangue, Hemocentro de São Paulo, SP 05403-000, Brazil

Received 11 November 2009; Accepted 9 January 2010

Academic Editor: Stefan Faderl

Copyright © 2010 Monika Conchon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. L. Sawyers, “Chronic myeloid leukemia,” The New England Journal of Medicine, vol. 340, no. 17, pp. 1330–1340, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Faderl, M. Talpaz, Z. Estrov et al., “The biology of chronic myeloid leukemia,” The New England Journal of Medicine, vol. 341, no. 3, pp. 164–172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” The New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Lichtman and J. Liesveld, “Acute myelogenous leukemia,” in Williams Hematology, E. Beutler, M. Lichtman, B. Coller et al., Eds., vol. 1047, McGraw-Hill, New York, NY, USA, 6th edition, 2001. View at Google Scholar
  5. M. S. Bazarbashi, M. R. Smith, C. Karanes, I. Zielinski, and C. R. Bishop, “Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy,” American Journal of Hematology, vol. 38, no. 3, pp. 235–237, 1991. View at Google Scholar · View at Scopus
  6. F. J. Strobl, K. V. Voelkerding, and E. P. Smith, “Management of chronic myeloid leukemia during pregnancy with leukapheresis,” Journal of Clinical Apheresis, vol. 14, no. 1, pp. 42–44, 1999. View at Google Scholar · View at Scopus
  7. M. Celiloglu, S. Altunyurt, and B. Unbar, “Hydroxyurea treatment for chronic myeloid leukemia during pregnancy,” Acta Obstetricia et Gynecologica Scandinavica, vol. 79, no. 9, pp. 803–804, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Patel, I. A. F. Dukes, and J. C. Hull, “Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report,” American Journal of Obstetrics and Gynecology, vol. 165, no. 3, pp. 565–566, 1991. View at Google Scholar · View at Scopus
  9. M. R. Baer, H. Ozer, and K. A. Foon, “Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia,” British Journal of Haematology, vol. 81, no. 2, pp. 167–169, 1992. View at Google Scholar · View at Scopus
  10. C. Baykal, N. Zengin, F. Coşkun et al., “Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report,” European Journal of Gynaecological Oncology, vol. 21, no. 1, pp. 89–90, 2000. View at Google Scholar · View at Scopus
  11. M. Kuroiwa, H. Gondo, K. Ashida et al., “Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy,” American Journal of Hematology, vol. 59, no. 1, pp. 101–102, 1998. View at Google Scholar · View at Scopus
  12. GLEEVEC (imatinib mesylate) [package Insert]: East Hanover, 2001.
  13. Tasigna: (nilotinib) [package Insert]: East Hanover NNPC, 2007.
  14. Sprycel [package insert]. Princeton NB-MS, 2007.
  15. S. M. Pye, J. Cortes, P. Ault et al., “The effects of imatinib on pregnancy outcome,” Blood, vol. 111, no. 12, pp. 5505–5508, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Cole, H. Kantarjian, P. Ault et al., “Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature,” Clinical Lymphoma & Myeloma, vol. 9, no. 4, pp. 324–327, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. N. P. Shah, C. Tran, F. Y. Lee et al., “Overriding imatinib resistance with a novel ABL kinase inhibitor,” Science, vol. 305, no. 5682, pp. 399–401, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. S. Tokarski, J. A. Newitt, C. Y. Chang et al., “The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants,” Cancer Research, vol. 66, no. 11, pp. 5790–5797, 2006. View at Google Scholar
  19. J. Cortes, S. O'Brien, P. Ault et al., “Pregnancy outcomes among patients with chronic myeloid leukemia treated with Dasatinib,” Blood, vol. 112, 2008, Abstract no. 3230. View at Google Scholar
  20. M. Conchon, S. S. Sanabani, and I. Bendit, “Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study,” Journal of Hematology and Oncology, vol. 42, no. 2, 2009. View at Publisher · View at Google Scholar · View at PubMed
  21. P. Ault, H. Kantarjian, S. O'Brien et al., “Pregnancy among patients with chronic myeloid leukemia treated with imatinib,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1204–1208, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. L. Garderet, R. Santacruz, V. Barbu et al., “Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib,” Haematologica, vol. 92, no. 1, pp. e9–e10, 2007. View at Publisher · View at Google Scholar · View at Scopus